Viewing Study NCT05404906



Ignite Creation Date: 2024-05-06 @ 5:43 PM
Last Modification Date: 2024-10-26 @ 2:34 PM
Study NCT ID: NCT05404906
Status: RECRUITING
Last Update Posted: 2022-08-19
First Post: 2022-05-31

Brief Title: AZA Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Sponsor: The First Affiliated Hospital of Soochow University
Organization: The First Affiliated Hospital of Soochow University

Study Overview

Official Title: Randomized Multicenter Phase 3 Study of Azacytidine AZA Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy
Status: RECRUITING
Status Verified Date: 2022-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival RFS for younger adults with favorable-risk acute myeloid leukemia AML who remained in first complete remission CR1 following intensive consolidation
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None